SCHEMBL482339

SCHEMBL482339

CC(=O)N1c2cc3c(cc2C(OC(N)=O)CC1C)OC(Cc1ccccc1)C(=O)N3

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 2/20 0.38
HSD17B10 Q99714 2/20 0.37
ALOX15 P16050 1/20 0.37
NPSR1 Q6W5P4 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
XIAP P98170 1/20 0.35
BIRC2 Q13490 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
BRD2 P25440 2/20 0.35
BRD3 Q15059 2/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
F2 P00734 2/20 0.34
F10 P00742 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL482474 0.83 SMN1; SMN2 (0.45) BRD4SMN1; SMN2TSHRLMNANPSR1
SCHEMBL483271 0.82 BRD4 (0.41) BRD4HSD17B10ALOX15MEN1KMT2A
SCHEMBL483269 0.72 NR3C2 (0.41) LMNAMAPTPTGDR2
SCHEMBL482338 0.72 NR3C2 (0.38) LMNAMEN1KMT2AMAPTALDH1A1
SCHEMBL483265 0.67 TSHR (0.35) TSHR
SCHEMBL483264 0.66 PTGDR2 (0.44) BRD4SMN1; SMN2TSHRLMNANPSR1
SCHEMBL482473 0.66 ABCB1 (0.40) BRD4SMN1; SMN2TSHRNPSR1
SCHEMBL12095227 0.66 BRD4 (0.51) BRD4SMN1; SMN2TSHRLMNABRD2
SCHEMBL12095226 0.66 BRD4 (0.51) BRD4SMN1; SMN2TSHRLMNABRD2
SCHEMBL12095224 0.66 BRD4 (0.51) BRD4SMN1; SMN2TSHRLMNABRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604030-B2 Fused piperidine compound and pharmaceutical containing same KOWA COMPANY, LTD. (JP) 2013-12-10 US disclosed
US-20120108581-A1 FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME KOWA COMPANY, LTD (JP) 2012-05-03 US disclosed
EP-2412710-A1 FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108581-A1 FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME EPOR, JAK2, HBZ BRD4 1271/4885SMN1; SMN2 1440/4885TSHR 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.